Front-line lung cancer a [$20 billion annual sales]. [$20 BILLION, EACH YEAR, ONE INDICTION]: Thank you, hutschi, for this Roche coverage. All the major BP's will compete vigorously to somehow dominate this most important indication and market, plus the many other indications and markets.
PPHM's anti-PS, Bavituximab, could end up being critical in helping to establish the immuno-oncology dominance by providing enhanced immune efficacy and safety across this space for the various anti-PD IOs through to the CAR T technologies.
"Lung cancer is by far the biggest oncology market and first-line treatment provides access to the most patients, opening up potential annual sales forecast by some analysts at $20 billion."
IMO
sunstar
News 
Market Data 
Discover 
AI
